Tomáš Bolek1, Matej Samoš2, Ingrid Škorňová3, Lucia Stančiaková3, Ján Staško3, Peter Galajda1, Peter Kubisz3, Marián Mokáň1. 1. Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovak Republic. 2. Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovak Republic. matej.samos@gmail.com. 3. Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Centre of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic.
Abstract
BACKGROUND: The number of elderly individuals with non-valvular atrial fibrillation (NV-AF) requiring long-term anticoagulation is rising. The pharmacokinetics of oral anticoagulants in elderly individuals may differ from that for younger patients. The aim of this study was to assess the dabigatran levels in elderly patients with NV-AF. PATIENTS AND METHODS: A pilot prospective post-marketing study in patients with NV-AF on dabigatran therapy was performed; we enrolled 21 consecutive elderly patients (aged ≥ 75 years) on a reduced dabigatran regimen (110 mg twice daily) and compared them with 13 younger (≤ 70 years) individuals on reduced dabigatran therapy due to renal impairment and with 16 younger patients on standard dabigatran therapy (150 mg twice daily). Blood samples were taken for the assessment of dabigatran trough and peak levels. Dabigatran levels were measured with the Hemoclot® Thrombin Inhibitor Assay. RESULTS: There were significant differences in dabigatran trough levels when comparing elderly patients on reduced dabigatran with non-elderly patients on reduced dabigatran (99.3 ± 73.6 vs 51.6 ± 25.6 ng/mL; p < 0.01). Similarly, the detected dabigatran peak levels were significantly higher in elderly patients on reduced dabigatran compared with non-elderly patients on reduced dabigatran (173.4 ± 116.2 vs 116.1 ± 19.1 ng/mL; p < 0.01). No significant differences in dabigatran trough and peak levels were found when comparing elderly patients on reduced dabigatran with non-elderly patients on standard dabigatran therapy. CONCLUSION: This pilot study demonstrated that elderly patients on reduced dabigatran exhibit significantly higher dabigatran levels than younger individuals on a reduced regimen, and similar levels compared with younger individuals on standard dabigatran.
BACKGROUND: The number of elderly individuals with non-valvular atrial fibrillation (NV-AF) requiring long-term anticoagulation is rising. The pharmacokinetics of oral anticoagulants in elderly individuals may differ from that for younger patients. The aim of this study was to assess the dabigatran levels in elderly patients with NV-AF. PATIENTS AND METHODS: A pilot prospective post-marketing study in patients with NV-AF on dabigatran therapy was performed; we enrolled 21 consecutive elderly patients (aged ≥ 75 years) on a reduced dabigatran regimen (110 mg twice daily) and compared them with 13 younger (≤ 70 years) individuals on reduced dabigatran therapy due to renal impairment and with 16 younger patients on standard dabigatran therapy (150 mg twice daily). Blood samples were taken for the assessment of dabigatran trough and peak levels. Dabigatran levels were measured with the Hemoclot® Thrombin Inhibitor Assay. RESULTS: There were significant differences in dabigatran trough levels when comparing elderly patients on reduced dabigatran with non-elderly patients on reduced dabigatran (99.3 ± 73.6 vs 51.6 ± 25.6 ng/mL; p < 0.01). Similarly, the detected dabigatran peak levels were significantly higher in elderly patients on reduced dabigatran compared with non-elderly patients on reduced dabigatran (173.4 ± 116.2 vs 116.1 ± 19.1 ng/mL; p < 0.01). No significant differences in dabigatran trough and peak levels were found when comparing elderly patients on reduced dabigatran with non-elderly patients on standard dabigatran therapy. CONCLUSION: This pilot study demonstrated that elderly patients on reduced dabigatran exhibit significantly higher dabigatran levels than younger individuals on a reduced regimen, and similar levels compared with younger individuals on standard dabigatran.
Authors: Mandy N Lauw; John W Eikelboom; Michiel Coppens; Lars Wallentin; Salim Yusuf; Michael Ezekowitz; Jonas Oldgren; Juliet Nakamya; Jia Wang; Stuart J Connolly Journal: Heart Date: 2017-02-17 Impact factor: 5.994
Authors: Charles V Pollack; Paul A Reilly; Joanne van Ryn; John W Eikelboom; Stephan Glund; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Chak-Wah Kam; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Gordon Royle; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Peter Verhamme; Bushi Wang; Laura Young; Jeffrey I Weitz Journal: N Engl J Med Date: 2017-07-11 Impact factor: 91.245
Authors: Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin Journal: J Am Coll Cardiol Date: 2013-09-27 Impact factor: 24.094
Authors: Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz Journal: N Engl J Med Date: 2015-06-22 Impact factor: 91.245
Authors: Andreas Clemens; Siyang Peng; Sarah Brand; Martina Brueckmann; Anuraag Kansal; Jonathan Lim; Herbert Noack; Stephen Sander; Sonja Sorensen Journal: Am J Cardiol Date: 2014-07-02 Impact factor: 2.778
Authors: Tomáš Bolek; Matej Samoš; Lucia Stančiaková; Jela Ivanková; Ingrid Škorňová; Ján Staško; Peter Galajda; Peter Kubisz; Marián Mokáň Journal: Am J Ther Date: 2019 May/Jun Impact factor: 2.688
Authors: Eri Toda Kato; Robert P Giugliano; Christian T Ruff; Yukihiro Koretsune; Takeshi Yamashita; Robert Gabor Kiss; Francesco Nordio; Sabina A Murphy; Tetsuya Kimura; James Jin; Hans Lanz; Michele Mercuri; Eugene Braunwald; Elliott M Antman Journal: J Am Heart Assoc Date: 2016-05-20 Impact factor: 5.501
Authors: Ellis Gommans; René J E Grouls; Daan Kerkhof; Saskia Houterman; Tim Simmers; Carolien Van der Linden Journal: Eur J Hosp Pharm Date: 2020-09-25